TITLE

Canadian prescription drug costs surpass $18 billion

AUTHOR(S)
Morgan, Steve
PUB. DATE
May 2005
SOURCE
CMAJ: Canadian Medical Association Journal;5/10/2005, Vol. 172 Issue 10, p1323
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Reports on the growth in prescription drug costs in Canada in 2004. Trends in expenditures on pharmaceutical products from 1944 to 2004; Reasons cited for the increase; Implications for practitioners and policy makers.
ACCESSION #
16900831

 

Related Articles

  • Trends in outpatient prescription drug use and related costs in the US: 1998-2003. Wysowski, Diane K.; Governale, Laura A.; Swann, Joslyn // PharmacoEconomics;2006, Vol. 24 Issue 3, p233 

    Objective: To present a brief synopsis of trends in the number of prescriptions and retail costs of outpatient drugs dispensed in the US between 1998 and 2003.Methods: Data were extracted from IMS Health, the National Prescription Audit Plus and the National Disease and...

  • The Pricing of Breakthrough Drugs: Theory and Policy Implications. Levy, Moshe; Rizansky Nir, Adi // PLoS ONE;Nov2014, Vol. 9 Issue 11, p1 

    Pharmaceutical sales exceed $850 billion a year, of which 84% are accounted for by brand drugs. Drug prices are the focus of an ongoing heated debate. While some argue that pharmaceutical companies exploit monopolistic power granted by patent protection to set prices that are “too...

  • Policymakers eye increased prescription drug spending, PBM promotional activities. Wechsler, Jill // Formulary;Nov98, Vol. 33 Issue 11, p1147 

    Reports that United States policy makers are eyeing increased prescription drug spending and pharmacy benefit management promotional activities in light of the rising health care spending. Prediction for a major surge in health care spending; Congress' concern that developments are affecting...

  • What is the cost of administration really worth? Eder, Rob // Drug Store News;10/6/2003, Vol. 25 Issue 13, p14 

    Comments on the administrative costs of health care in the United States. Ways in which the rebate situation has made it impossible for a doctor to tell what drug is cheapest; Argument that the secretive rebate system of pharmacy benefits managers (PBM) moves more expensive drugs to the top of...

  • Prescription drug expenditures rising -- too fast?  // CMAJ: Canadian Medical Association Journal;5/10/2005, Vol. 172 Issue 10, p1261 

    Comments on the rising cost of prescription drugs in Canada. Rank of Canada among developed countries with the highest annual rate of prescription drug cost; Total cost of prescription drug cost in Canada in 2004; Discussion on the reasons for the rising cost of prescription drug in the country.

  • Copay assistance programs lead to higher healthcare costs.  // PharmacoEconomics & Outcomes News;10/22/2016, Vol. 764 Issue 1, p1 

    The article discusses findings of a study conducted by Peter Ubel of Duke University and Peter Bach of Memorial Sloan Kettering Cancer Center, on the impacts of copay assistance programs for expensive drugs in addressing the financial needs of patients and the risk of higher health care cost.

  • The Great Pharmacy Rip-off. Ragg, Mark // Bulletin with Newsweek;12/08/98, Vol. 117 Issue 6152, p26 

    Presents information on the deal between the Australian government under Hawke and the Pharmacy Guild over the price charged to the public for prescription drugs. The government and the pharmacists agreeing that the public should pay more; Secrecy about the agreement; Details on the various...

  • Drug costs continue to rise. Alfaro, Aura N. // Caribbean Business;7/1/1999, Vol. 27 Issue 25, p26 

    Reports that healthcare costs in Puerto Rico continue to rise. Biggest increase in prescription drug prices followed by hospitalization costs; Increase in drug costs for health insurers because many pharmacy chains are not honoring discounts; Pharmaceutical companies' move to advertise specific...

  • Pharmaceutical assistance programs walk a high wire while looking for ways to save money.  // State Health Watch;Aug2004, Vol. 11 Issue 8, p1 

    Reports on an increase in state pharmaceutical assistance program drug expenditures in the U.S., according to a report funded by The Commonwealth Fund in 2004. Increase in prescription claim costs between 1999 and 2000; Options available to states for controlling program utilization and costs;...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics